GHRP-2 Acetate

GHRP-2 (Pralmorelin) is a synthetic hexapeptide GHS-R1a agonist — among the first-generation GHRPs, it is studied for the strongest GH release per unit dose in research models. That potency is the reason it became the standard positive control in GH release assays. CAS: 158861-67-7. MW 817.9 Da. Decades of published data across multiple species and administration routes. If you need a well-characterized GHSR agonist with the widest published dataset, GHRP-2 is it.

Potency vs. Selectivity

In research models, GHRP-2 produces larger GH pulses than ipamorelin, but with less receptor selectivity. At the pituitary, it activates both GHS-R1a (GH release) and ACTH pathways, associated with elevated cortisol in research models. Prolactin rises mildly at higher doses. These off-target hormonal effects are the reason ipamorelin displaced GHRP-2 in protocols where clean GH release without cortisol confounding is required.

The off-targets are not always a problem. If the research question involves GHS-R pharmacology across pituitary cell types, ACTH axis cross-talk, or full characterization of ghrelin receptor signaling, those effects are part of the data. GHRP-2 is more useful than ipamorelin for those questions precisely because it is less selective. Comparison with GHRP-6 is also worth noting: GHRP-2 gives more GH per unit dose in research models; GHRP-6 is studied for stronger appetite stimulation through hypothalamic GHS-R activation.

Specifications

Storage: Lyophilized: −20°C, away from light. Once reconstituted: 2–8°C, use within 4 weeks.

Quality: Every product ships to a ≥98% supplier batch specification; selected lots are independently tested by Janoshik Analytical (HPLC + mass spectrometry; 99.3% average purity across published reports), searchable by batch code at certapeptides.com/verify. EU-based QC under CERTALAB S.R.L.

For research purposes only. Not for human consumption.